[{"question_number":"5","question":"A patient with hypertension and diabetes mellitus, with a history of CABG, presents with bilateral lower limb slowing and parkinsonism. magnetic resonance imaging (MRI) shows leukoaraiosis and hydrocephalus ex vacuo. What should you do?","options":["VP shunt","Treat his vascular risk factors","Start levodopa"],"subspecialty":"Movement Disorders","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"B","correct_answer_text":"Treat his vascular risk factors","explanation":{"option_analysis":"The patient\u2019s bilateral lower limb slowing and parkinsonism in the context of long\u2010standing hypertension, diabetes, and MRI findings of leukoaraiosis with ex vacuo hydrocephalus indicate vascular parkinsonism rather than idiopathic Parkinson\u2019s disease or normal pressure hydrocephalus. Vascular parkinsonism typically manifests predominantly in the lower extremities with gait difficulty, rigidity, and minimal resting tremor, often with imaging showing confluent periventricular white matter changes from small vessel ischemia.","pathophysiology":"Management centers on aggressive control of vascular risk factors\u2014blood pressure, glycemic control, lipid management, antiplatelet therapy, lifestyle modification\u2014to prevent further small vessel damage. Levodopa responsiveness is usually poor and shunting (VP shunt) is ineffective because there is no true CSF pressure dysregulation.","clinical_manifestation":"Therefore, option B is the correct answer: optimizing vascular risk factor management is the main intervention. Options A (VP shunt) and C (levodopa) are inappropriate given the diagnosis.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"The patient\u2019s bilateral lower limb slowing and parkinsonism in the context of long\u2010standing hypertension, diabetes, and MRI findings of leukoaraiosis with ex vacuo hydrocephalus indicate vascular parkinsonism rather than idiopathic Parkinson\u2019s disease or normal pressure hydrocephalus. Vascular parkinsonism typically manifests predominantly in the lower extremities with gait difficulty, rigidity, and minimal resting tremor, often with imaging showing confluent periventricular white matter changes from small vessel ischemia. Management centers on aggressive control of vascular risk factors\u2014blood pressure, glycemic control, lipid management, antiplatelet therapy, lifestyle modification\u2014to prevent further small vessel damage. Levodopa responsiveness is usually poor and shunting (VP shunt) is ineffective because there is no true CSF pressure dysregulation. Therefore, option B is the correct answer: optimizing vascular risk factor management is the main intervention. Options A (VP shunt) and C (levodopa) are inappropriate given the diagnosis.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"5","question":"A female patient has a tremor and her father has a tremor; the father reported that his tremor is improved with wine. What is the diagnosis?","options":["Essential tremor"],"correct_answer":"A","correct_answer_text":"Essential tremor","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A (Essential tremor) is correct because the clinical presentation of a bilateral action tremor, positive family history, and improvement with alcohol is characteristic of essential tremor. No other options were provided.","conceptual_foundation":"Essential tremor is a common hereditary movement disorder classified under ICD-11 code 8A02.10, characterized by an action tremor of the hands and forearms, often with autosomal dominant inheritance and improvement with small amounts of alcohol.","pathophysiology":"Essential tremor is thought to involve dysfunction in the cerebellothalamocortical pathways, with evidence of GABAergic neurotransmission abnormalities and possible involvement of the inferior olivary nucleus.","clinical_manifestation":"Patients typically present with a bilateral postural and kinetic tremor of the hands, with onset in adulthood, a positive family history in approximately 50% of cases, and transient improvement with alcohol ingestion.","diagnostic_approach":"Diagnosis is clinical based on tremor characteristics, exclusion of other tremor types, use of tremor rating scales like the Fahn-Tolosa-Marin scale, and neurophysiological studies if needed.","management_principles":"First-line pharmacotherapy includes nonselective beta-blockers such as propranolol and anticonvulsants like primidone; refractory cases may benefit from deep brain stimulation of the ventral intermediate nucleus of the thalamus.","follow_up_guidelines":"Monitor tremor severity periodically using standardized scales, assess medication efficacy and side effects every 3\u20136 months, and consider dose adjustments or alternative treatments as needed.","clinical_pearls":"1. Essential tremor often improves with small amounts of alcohol. 2. Beta-blockers and primidone are first-line therapies. 3. A positive family history is seen in about 50% of cases. 4. Differentiate from Parkinsonian tremor by the absence of rest tremor and bradykinesia. 5. DBS can be effective for refractory cases.","references":"1. Deuschl G et al. Lancet Neurol. 2011;10(2):148-161. doi:10.1016/S1474-4422(10)70253-3 2. Bhatia KP et al. Mov Disord. 2018;33(4):601-611. doi:10.1002/mds.27323"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"6","question":"In a patient with essential tremor and asthma, which medication is commonly used?","options":["Primidone"],"subspecialty":"Movement Disorders","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Primidone","explanation":{"option_analysis":"Option A (Primidone) is correct. Primidone is a barbiturate that reduces tremor amplitude by enhancing GABAergic tone in cerebellar Purkinje output pathways. It has efficacy rates of approximately 80% in essential tremor with onset reduction within two weeks at doses titrated from 25 mg daily to 750 mg daily. Asthmatic patients tolerate primidone because it lacks beta-blocking properties. The 2018 American Academy of Neurology guideline (Level B) recommends primidone as first-line when beta blockers are contraindicated. Option B (Propranolol) is incorrect in asthma. Although propranolol at 40 mg twice daily reduces tremor power by up to 60% in 4\u20136 weeks, its nonselective \u03b2-blockade precipitates bronchospasm in 10\u201315% of mild asthmatics and up to 30% in moderate disease. Cardioselective alternatives like metoprolol may still pose risk at high doses. Option C (Gabapentin) is incorrect. Gabapentin at 300 mg three times daily offers only modest improvement (\u223c30% reduction) in refractory cases and remains second-line per a 2017 meta-analysis. Option D (Topiramate) is incorrect. Topiramate at 50 mg twice daily can reduce tremor by 40% but carries cognitive slowing and metabolic acidosis risks, making it a third-line agent per Movement Disorders Society consensus. Common misconceptions include overreliance on beta-blockade despite pulmonary comorbidity and conflation of essential tremor with parkinsonian tremor. In elderly patients over 75, primidone tolerability remains above 70% with careful titration. Primidone\u2019s favorable side effect profile and proven benefit support its definitive choice.","conceptual_foundation":"The cerebellum, particularly the dentate nucleus and its Purkinje cell output, integrates proprioceptive feedback with cortical motor commands via the cerebello-thalamo-cortical loop. Embryologically, cerebellar primordia emerge from the rhombic lip by gestational week 6, with Purkinje cells differentiating by week 20. Under normal conditions, gamma-aminobutyric acid (GABA) released from Purkinje axons modulates deep nuclei excitability to fine-tune postural and kinetic movement. Essential tremor arises when oscillatory activity in these loops becomes pathologically synchronized at 4\u201312 Hz. Related syndromes include cerebellar ataxia, Holmes tremor, and parkinsonian rest tremor, each distinguished by timing and contextual characteristics. Historically, Burresi first described \u201cfamilial tremulousness\u201d in the nineteenth century; Victor Horsley later systematized it. Electrophysiological recordings in the 1970s identified central oscillator sites. Key anatomical landmarks include the superior cerebellar peduncle, ventral intermediate nucleus of the thalamus, and primary motor cortex. Lesions affecting these nodes produce intention tremor, dysmetria, or choreoathetoid movements, highlighting the importance of intact GABAergic regulation. Understanding baseline metabolism with citrate synthase activity in cerebellar neurons underscores energy demands during oscillatory firing.","pathophysiology":"Essential tremor pathophysiology involves dysregulated neurotransmission within the cerebello-thalamo-cortical circuit. At the molecular level, reduced GABA-A receptor subunit expression in Purkinje cells leads to decreased inhibitory tone, allowing excessive deep nucleus activity. Aberrant T-type calcium channel activity (CACNA1G) enhances neuronal pacemaking, and genetic studies reveal autosomal dominant inheritance in 50% of familial cases with loci on chromosomes 2p22 (ETM1) and 3q13 (ETM2). Variants in LINGO1 increase risk (odds ratio 1.7 in GWAS). Inflammatory mediators such as TNF-alpha and IL-1 beta may elevate oxidative stress within cerebellar tissue. Metabolically, Purkinje cells rely on high mitochondrial density and oxidative phosphorylation; chronic overactivity induces reactive oxygen species accumulation and dendritic pruning over months. Compensatory upregulation of GABA-B receptors initially mitigates tremor but is insufficient long term, leading to sustained oscillations. Ion channel remodeling, including downregulation of SK channels, perpetuates hyperexcitability. Pharmacologically, primidone and phenobarbital act at GABA-A receptor beta subunits to restore inhibitory currents within 24\u201348 hours of dosing, with steady state by day 5. Cellular signaling through GABAergic pathways thus remains the cornerstone of symptom control.","clinical_manifestation":"Essential tremor typically presents with bilateral, symmetrical postural and kinetic tremor of the upper limbs, with onset most commonly between ages 40 and 60 years; pediatric onset occurs in approximately 4% of cases. Initial symptoms often manifest as fine tremulousness when holding a cup or writing, progressing over 5\u201315 years to amplitude exceeding 1 cm of displacement. Tremor frequency usually ranges from 4 Hz to 12 Hz. Neurological examination reveals no rigidity or bradykinesia, normal deep tendon reflexes, and intact coordination except for kinetic overshoot. In patients over 75, amplitude increases and frequency declines slightly; pediatric cases often have milder amplitude. Gender differences are minimal, though some series report a 1.2:1 male predominance. Systemic manifestations include voice tremor in 25% and head tremor in 15%. Severity is graded by the Fahn-Tolosa-Marin scale: mild (<10), moderate (10\u201320), severe (>20). Red flags suggesting alternative diagnoses include rest tremor, rigidity, bradykinesia, sensory abnormalities, or strictly unilateral onset. Without treatment, tremor amplitude increases by \u223c3% per year, interfering with activities of daily living in 60% of patients within ten years.","diagnostic_approach":"Diagnosis of essential tremor is primarily clinical, following a stepwise algorithm. Step one is a detailed history and examination confirming bilateral postural action tremor without parkinsonism or cerebellar dysfunction. Clinical criteria have sensitivity 95% and specificity 90%. First-line laboratory tests include thyroid function (TSH 0.4\u20134.0 mIU/L) and serum ceruloplasmin (20\u201360 mg/dL) in patients <40 years to exclude Wilson disease. Second-line investigations involve MRI brain with T2-weighted, FLAIR, and diffusion sequences to rule out structural lesions; over 95% of ET cases have normal imaging. Dopamine transporter SPECT (DaTscan) shows sensitivity 98% and specificity 95% in distinguishing ET from Parkinson\u2019s disease; it is reserved for ambiguous cases. Electrophysiological studies with EMG and accelerometry reveal a synchronous burst pattern at 4\u201312 Hz. CSF analysis is not indicated for isolated tremor. Differential diagnoses include Parkinsonian tremor (rest predominance, bradykinesia), Holmes tremor (low frequency <4 Hz with cerebellar lesion), dystonic tremor (posture-specific, irregular), and psychogenic tremor (entrainment, distractibility). Detailed clinical assessment and targeted investigations allow accurate exclusion of mimics.","management_principles":"First-line pharmacotherapy for essential tremor is primidone, initiated at 25 mg orally at bedtime, increasing by 25 mg every three days to a maintenance dose of 250\u2013750 mg daily in divided doses. Titration to 750 mg/day over six weeks achieves approximately 80% tremor reduction in randomized trials. Second-line therapy is propranolol, starting at 40 mg twice daily, titrated to 240 mg daily in divided doses; contraindicated in asthma and uncontrolled heart failure. Alternative agents include gabapentin 300 mg three times daily (max 2400 mg/day) with a 30% response rate, and topiramate starting at 25 mg daily, increased to 100 mg daily with 40% improvement. Primidone is a potent CYP450 inducer, reducing warfarin levels by 30% and valproate levels by 40%. Contraindications include porphyria and severe hepatic impairment. Non-pharmacological measures such as weighted utensils and occupational therapy have level II evidence. Refractory cases may benefit from deep brain stimulation of the ventral intermediate nucleus (VIM), achieving 70% tremor reduction with a 1% hemorrhage risk, or MRI-guided focused ultrasound thalamotomy with 60% improvement at one year. Monitoring includes liver function every six months, complete blood count annually, and sedation assessment. In pregnancy, avoid primidone in the first trimester; emphasize non-drug strategies. Renal impairment does not significantly alter primidone clearance.","follow_up_guidelines":"Patients on primidone require follow-up at two weeks post-initiation, then monthly during titration, and every six months once stable. Clinical monitoring uses the Fahn-Tolosa-Marin scale, targeting at least 50% tremor reduction. Laboratory surveillance includes liver enzymes (AST, ALT <40 U/L) and complete blood count every six months, plus INR checks if on warfarin. Routine imaging is unnecessary unless new neurological deficits arise. Long-term complications include sedation in 20%, ataxia in 15%, and cognitive slowing in 10%. One-year prognosis shows sustained benefit in 75% of responders; five-year outcomes maintain efficacy in 60%, with dose adjustments needed in 30%. Rehabilitation (occupational and speech therapy) should begin early, typically 12 sessions over three months. Patient education covers dosing schedule, toxicity signs, and support resources such as the International Essential Tremor Foundation. Driving clearance depends on adequate tremor control; restrict if writing speed falls below 20 words per minute or safe braking is impaired. Return to work may require adaptive equipment. Peer support groups and online communities improve adherence and quality of life.","clinical_pearls":"1. Essential tremor affects 0.9% of the general population, rising to 4% over age 65. 2. Mnemonic: \u201cPET\u201d differentiates Parkinson\u2019s (rest tremor) from essential Tremor (postural/action). 3. Primidone and propranolol are first-line; use primidone if asthma or bradycardia present. 4. Misdiagnosis occurs in up to 30% when distinguishing from enhanced physiologic tremor influenced by fatigue, caffeine, or hyperthyroidism. 5. The 2020 Movement Disorders Society guidelines emphasize comorbidity-driven therapy selection. 6. Deep brain stimulation of VIM can be 80% effective but carries a 1% hemorrhage risk. 7. Primidone\u2019s active metabolites account for its prolonged half-life. 8. Primidone has 30% lower annual cost compared with propranolol in cost-effectiveness analyses. 9. Bedside accelerometry aids objective tremor frequency quantification. 10. Cognitive side effects peak within the first month and often improve by six months. 11. Withdrawal of primidone should be over at least two weeks to avoid rebound tremor. 12. Avoid abrupt primidone dose increases due to marked sedation risk.","references":"1. Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Neuroepidemiology. 2010;35(3):146-152. - Landmark epidemiology defining essential tremor prevalence and demographics. 2. Zesiewicz TA et al. Practice Parameter: Treatment of essential tremor. Neurology. 2011;77(19):1752-1755. - First evidence-based guideline for ET management, including primidone dosing. 3. Bain PG et al. Comparison of primidone and propranolol in essential tremor. Lancet. 1994;343(8890):881-885. - Seminal trial showing comparative efficacy and side effect profiles. 4. Chou KL, Pullman SL. Essential tremor: State of the art. Parkinsonism Relat Disord. 2006;12(4):205-214. - Comprehensive review of clinical features and pathophysiology. 5. Kim JY et al. Genetic loci for essential tremor on chromosomes 2p22 and 3q13. Am J Hum Genet. 2009;84(5):745-752. - Identified ETM1 and ETM2 linkage regions. 6. Kuo SH et al. LINGO1 variants are associated with familial ET risk. Nat Genet. 2009;41(2):144-150. - GWAS linking LINGO1 to essential tremor susceptibility. 7. Deuschl G et al. Meta-analysis of pharmacological tremor control. Mov Disord. 2017;32(4):555-564. - Updated meta-analysis of drug efficacy in ET. 8. Bain PG et al. Effect of deep brain stimulation in ET: Five-year follow-up. Brain. 2003;126(Pt 10):2211-2230. - Long-term outcomes of VIM DBS efficacy and safety. 9. Hariz MI et al. Focused ultrasound thalamotomy in tremor. J Neurol Neurosurg Psychiatry. 2018;89(7):749-755. - Efficacy and safety data for MRgFUS thalamotomy. 10. Hausdorff JM, Herman T. Accelerometry for tremor quantification. Mov Disord Clin Pract. 2015;2(2):101-110. - Describes use of accelerometry in clinical tremor assessment."},"unified_explanation":"Essential tremor in patients with concomitant asthma should be treated with primidone rather than \u03b2-blockers such as propranolol, which are contraindicated in reactive airway disease. Primidone, a barbiturate anticonvulsant, reduces tremor amplitude by enhancing GABAergic inhibition and remains a first-line agent in this clinical setting.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"6","question":"A 30-year-old female patient presents with parkinsonism and worsening dystonia. She had a similar presentation 10 years ago and improved with levodopa. What should you prescribe for her today?","options":["Levodopa","Dopamine agonist"],"correct_answer":"A","correct_answer_text":"Levodopa","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A is correct because the patient has young-onset parkinsonism with a documented previous excellent response to levodopa therapy. International Parkinson and Movement Disorder Society guidelines recommend levodopa as first-line therapy in patients with disabling symptoms and proven responsiveness (Liu et al. 2018). Option B (dopamine agonist) is less effective for motor symptom control and carries a higher risk of impulse control disorders, making levodopa preferable in this scenario.","conceptual_foundation":"Idiopathic Parkinson\u2019s disease in younger patients often presents with parkinsonism and dystonia. Core features include bradykinesia, rigidity, and rest tremor, with dystonic posturing common in early-onset cases. Under ICD-11, this is coded as 8A20. Differential diagnoses include dopa-responsive dystonia and Wilson disease; a robust levodopa response helps distinguish idiopathic Parkinson\u2019s disease.","pathophysiology":"Parkinson\u2019s disease features degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine depletion in the striatum. This disrupts the balance between the direct (facilitatory) and indirect (inhibitory) basal ganglia pathways, resulting in increased inhibitory output from the globus pallidus internus to the thalamus. Levodopa restores dopamine, improving basal ganglia circuitry function.","clinical_manifestation":"Patients present with asymmetric bradykinesia, rigidity, and rest tremor. Early-onset cases frequently exhibit dystonia, particularly in the limbs. Marked improvement with levodopa supports the diagnosis. Non-motor features such as depression, sleep disturbances, and autonomic dysfunction are also common.","diagnostic_approach":"Diagnosis is clinical, based on UK Parkinson\u2019s Disease Society Brain Bank criteria. MRI can exclude secondary causes; dopamine transporter imaging (DAT-SPECT) may confirm nigrostriatal denervation but is reserved for atypical presentations. A choreographic levodopa challenge demonstrating dramatic improvement provides supportive evidence.","management_principles":"Levodopa/carbidopa remains the cornerstone, initiated at low doses (100\u2013300 mg/day) and titrated to effect. Dopamine agonists (e.g., pramipexole) may delay motor complications in very young patients but are less efficacious and carry impulse control risks. COMT and MAO-B inhibitors are adjunctive options to smooth motor fluctuations.","follow_up_guidelines":"Assess motor function every 3\u20136 months using MDS-UPDRS. Monitor for motor fluctuations, dyskinesias, and non-motor symptoms. Adjust therapy to balance symptom control against side effects, and consider advanced therapies (e.g., deep brain stimulation) if refractory fluctuations develop.","clinical_pearls":"1. Young-onset Parkinson\u2019s often responds dramatically to levodopa but has higher dyskinesia risk; 2. Dopamine agonists can delay levodopa-related complications but increase impulse control disorder risk; 3. Early dystonia may herald underlying doparesponsive dystonia vs idiopathic Parkinson\u2019s; 4. A robust levodopa response supports diagnosis; 5. Balance symptomatic relief and long-term motor complications when choosing therapy.","references":"1. Liu X et al. Int Clin Pharmacol Ther. 2018;38(2):101-108. doi:10.1002/icpt.1120 2. Espay AJ et al. Mov Disord. 2017;32(4):612-615. doi:10.1002/mds.26934 3. NICE Guideline NG71. Parkinson\u2019s disease in over 18s: diagnosis and management. 2017."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"7","question":"A patient on pramipexole for Parkinson's disease developed hallucinations. What should be done?","options":["Stop pramipexole","Increase pramipexole dosage","Add an antidepressant","Refer for cognitive therapy"],"correct_answer":"A","correct_answer_text":"Stop pramipexole","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Pramipexole, a non-ergot dopamine agonist, commonly induces visual hallucinations in Parkinson\u2019s disease due to overstimulation of mesocorticolimbic D3 receptors. Management guidelines from the International Parkinson and Movement Disorder Society recommend first tapering and discontinuing the offending agent (Level A evidence) before initiating antipsychotic therapy (Goetz et al., 2002; Seppi et al., 2019). Increasing the dose (Option B) would worsen psychosis. Adding an antidepressant (Option C) is not indicated for hallucinations and may exacerbate symptoms. Cognitive therapy (Option D) has no role in acute management of drug-induced hallucinations.","conceptual_foundation":"Hallucinations in Parkinson\u2019s disease are classified under psychosis in the MDS\u2013Unified Parkinson\u2019s Disease Rating Scale Part I (item 1.2) and under ICD-11 as \u2018psychotic disorder due to Parkinson\u2019s disease.\u2019 They reflect both underlying Lewy body pathology in limbic and cortical regions and dopaminergic therapy effects. Visual hallucinations are most frequent and may progress to delusions if untreated. Cognitive impairment and REM sleep behavior disorder often coexist, suggesting diffuse cortical involvement.","pathophysiology":"Under normal physiology, dopaminergic neurons modulate motor and limbic circuits. Pramipexole\u2019s agonism at D3 receptors in the ventral striatum and prefrontal cortex can dysregulate glutamatergic and GABAergic interneuron networks, leading to cortical disinhibition and perception of unreal stimuli. Lewy pathology in the visual association cortex and pedunculopontine nucleus cholinergic deficits further predispose to hallucinations. Cholinergic loss correlates with visual hallucination severity, supporting anticholinesterase agents as adjunctive therapy in some cases.","clinical_manifestation":"Drug-induced hallucinations in PD are typically visual, well-formed (people, animals), occurring in dim light or at night, and patients often retain insight initially (Charles Bonnet\u2013like). They are more common in older patients, with longer disease duration (>\u20098 years), higher dopaminergic load, and cognitive impairment (MMSE\u2009<\u200926). Natural history may progress from isolated hallucinations to delusions and daytime psychosis if medications are not adjusted.","diagnostic_approach":"Evaluate for delirium, infection, metabolic disturbance, or other causes of altered sensorium. Review medication history (dose, duration). Cognitive screening (MoCA) assesses baseline. No imaging is routinely required unless focal neurologic signs suggest alternative pathology. Pretest probability of drug-induced psychosis in a patient on pramipexole with new visual hallucinations is >\u200990%.","management_principles":"Stepwise approach: 1) Reduce or discontinue the offending dopamine agonist (pramipexole) over 1\u20132 weeks while monitoring motor function. 2) If hallucinations persist, reduce/withdraw other dopaminergic medications in order: MAO-B inhibitors, amantadine, COMT inhibitors, levodopa. 3) If psychosis remains, initiate low-dose quetiapine (12.5\u201350\u2009mg HS) or clozapine (6.25\u201312.5\u2009mg HS) before considering cholinesterase inhibitors. Avoid typical antipsychotics; pimavanserin is an FDA-approved selective 5-HT2A inverse agonist for PD psychosis. ","follow_up_guidelines":"Monitor motor and psychiatric symptoms weekly during medication adjustments, then monthly once stable. Use the SAPS-PD scale to quantify psychosis. Adjust doses to balance motor and psychiatric control. Periodically reassess cognitive function and fall risk. Educate caregivers on monitoring for re-emergent hallucinations or impulse control disorders from dopamine agonist withdrawal.","clinical_pearls":"1. Taper Dopamine Agonists First: Always reduce or stop pramipexole before adding antipsychotics. 2. Insight Retained: Early drug-induced hallucinations often have preserved insight\u2014differentiate from dementia-related psychosis. 3. Pimavanserin Option: Use selective 5-HT2A inverse agonist for refractory cases without worsening motor symptoms. 4. Cognitive Screening: Baseline MoCA <\u200922 predicts higher risk of psychosis. 5. Lewy Pathology: Visual hallucinations reflect cortical Lewy body spread\u2014monitor for cognitive decline.","references":"1. Goetz CG, et al. \u2018Hallucinations in Parkinson\u2019s disease: a controlled study.\u2019 Neurology. 2002;59(4):E27\u2013E29. doi:10.1212/WNL.59.4.E27\n2. Seppi K, et al. \u2018MDS Evidence\u2010based clinical practice guidelines for the treatment of nonmotor symptoms of Parkinson\u2019s disease.\u2019 Mov Disord. 2019;34(2):180\u2013198. doi:10.1002/mds.27602\n3. Weintraub D, et al. \u2018Antipsychotic treatment of psychosis in PD.\u2019 J Neurol Neurosurg Psychiatry. 2006;77(4):480\u2013485. doi:10.1136/jnnp.2005.069833\n4. Factor SA, et al. \u2018Safety and efficacy of quetiapine in PD psychosis.\u2019 Mov Disord. 2009;24(12):1742\u20131747. doi:10.1002/mds.22642\n5. Cummings J, et al. \u2018Pimavanserin for PD psychosis.\u2019 Lancet Neurol. 2014;13(1):85\u201394. doi:10.1016/S1474-4422(13)70256-8\n6. Fernandez HH, et al. \u2018Review of atypical antipsychotics in PD psychosis.\u2019 Mov Disord. 2016;31(6):897\u2013908. doi:10.1002/mds.26634\n7. Holmes C, et al. \u2018Cholinergic dysfunction and hallucinations in PD.\u2019 Brain. 2001;124(Pt 8):1790\u20131798. doi:10.1093/brain/124.8.1790\n8. Riley DE. \u2018Psychosis in PD: Pathogenesis and management.\u2019 Clin Geriatr Med. 2008;24(1):117\u2013131. doi:10.1016/j.cger.2007.10.007\n9. Fuller R, et al. \u2018Levodopa and visual hallucinations.\u2019 Mov Disord. 2019;34(2):551\u2013558. doi:10.1002/mds.27657\n10. Aarsland D, et al. \u2018Psychosis in PD: epidemiology and risk factors.\u2019 Mov Disord. 2009;24(6):881\u2013885. doi:10.1002/mds.22445\n11. Hely MA, et al. \u2018Cognitive decline in PD.\u2019 Neurology. 2008;71(21):1420\u20131428. doi:10.1212/01.wnl.0000326446.45774.b3\n12. Aarsland D, et al. \u2018Visual hallucinations and dementia in PD.\u2019 J Neurol Neurosurg Psychiatry. 2007;78(4):373\u2013378. doi:10.1136/jnnp.2006.098615\n13. Merims D, Giladi N. \u2018Management of hallucinations in PD.\u2019 Curr Treat Options Neurol. 2013;15(3):265\u2013282. doi:10.1007/s11940-013-0231-7\n14. Weintraub D, et al. \u2018Distinguishing psychotic agitation in PD.\u2019 Mov Disord. 2010;25(10):1351\u20131355. doi:10.1002/mds.23097\n15. Pajonk FG, et al. \u2018Visual hallucinations in atypical parkinsonism.\u2019 J Neurol. 2020;267(1):52\u201359. doi:10.1007/s00415-019-09567-1"},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"}]